Because estrone is produced in tissue rather than a single gland, its level reflects body composition, age and menopausal status as much as ovarian activity. That makes it a useful second lens on estrogen status, not a stand-alone verdict.
Estrone, written as E1 on most lab reports, is one of the three main estrogens the human body produces, and it is the form that circulates in the largest relative amount later in life.
It is a steroid hormone, built from cholesterol through a series of enzyme steps that run in several tissues at once. The step that matters most for estrone is aromatase, the enzyme that converts androgens into estrogens. Aromatase takes androstenedione, an androgen released largely by the adrenal glands and the ovaries, and turns it into estrone. Research describes estrogen production as heavily peripheral, with a large share formed outside the gonads by conversion of circulating androgen precursors in tissue such as fat, skin, bone and liver 1.
Two further features explain why estrone behaves the way it does on a lab report.
The first is storage. Much of the estrogen in blood is not free hormone at all, it is estrone sulfate, an inactive, water soluble form with a long half life that works as a reservoir. Enzymes can remove the sulfate group and return estrone to the active pool. That buffering is one reason estrone tends to move more slowly and less sharply than the ovarian estrogen swings seen across a menstrual cycle.
The second is interconversion. Estrone and the more potent ovarian estrogen convert back and forth through a single enzyme family, so neither number stands alone. A higher estrone reading can reflect more production, more conversion, or slower clearance through the liver and gut.
That is the short version. Estrone is a weaker estrogen at the receptor, made largely outside the ovaries, held in a sulfate reservoir, and constantly trading places with its stronger relative.
Estradiol (E2) is the most potent of the main estrogens and the dominant one through the reproductive years, produced mainly by the ovaries under pituitary signalling. Estrone and estradiol interconvert, so the two numbers are best read together rather than separately.
This page stays on estrone. For what estradiol is, how it is measured, the ranges labs report and how to think about a result, see the Estradiol guide, which covers that marker in full.
Estrone takes over after menopause because the ovarian source of estradiol fades while the peripheral source of estrone does not.
During the reproductive years, the ovarian follicle is the main estrogen factory, and estradiol output rises and falls with the cycle. As follicles are depleted, that output declines and pituitary signalling rises, which is why FSH climbs while estradiol falls. What continues is the other pathway. The adrenal glands keep releasing androgen precursors, and aromatase in fat, skin, bone, muscle and liver keeps converting them into estrone 1. Conversion capacity does not switch off with the ovaries, so estrone becomes the estrogen present in the largest amount.
This matters for interpretation in a practical way. After menopause, estradiol often sits near the lower limit of what an ordinary assay can resolve, so a single low estradiol number says little by itself. Estrone, drawn from a larger and slower pool, can still be measurable, and a clinician may use it to get a fuller sense of overall estrogen exposure.
It also changes what drives the result. Before menopause, the biggest variable is where someone is in the cycle. After menopause, the biggest variables are the amount of androgen precursor available and the amount of tissue converting it. That is why two people of the same age and menopausal status can return noticeably different estrone results with no obvious symptom difference between them.
Fat tissue is one of the body's largest sites of aromatase activity, so body composition is a direct input into how much estrone gets made.
Adipose tissue is metabolically active. It takes up circulating androgens and converts a fraction of them to estrogen, which is then released back into the bloodstream. Research describes this peripheral conversion as a major contributor to total estrogen production, particularly where gonadal output is low 1. The practical implication is that total estrone in blood depends partly on how much converting tissue is present and how active it is, not only on what the ovaries or adrenals release.
That gives estrone a different character from most reproductive hormones. It behaves partly like a metabolic marker. Changes in body composition, which happen slowly, tend to show up in estrone slowly too. A result taken during a period of rapid weight change may not represent a settled baseline, which is one reason repeat testing under similar conditions is more informative than a single snapshot.
None of this makes a number good or bad on its own. A higher estrone result in someone with more adipose mass is a physiological observation, not a diagnosis, and the question a clinician asks next is what the rest of the panel and the clinical picture show. Body composition is one plausible contributor among several, and it sits alongside age, menopausal status, adrenal androgen output and liver handling of hormones.
Not exactly. Estrone binds estrogen receptors more weakly than estradiol, but weaker is not the same as simply smaller.
Research suggests that estrone has actions distinct from those of estradiol rather than functioning only as a diluted version of it 2. Receptor binding is only the first step. What a hormone does in a given tissue depends on which receptor subtypes are present, which co-regulator proteins are recruited, how much of the hormone is converted locally, and what else is competing for the same receptor at the same time.
Competition is the part most people miss. When a weaker agonist occupies a receptor, it can keep a stronger one from binding there. Studies suggest that estrone can behave as a partial antagonist of estradiol in the normal breast 3. In that setting, the ratio between the two estrogens may carry information the individual numbers do not.
Two things follow for anyone reading their own results. First, a higher estrone value is not automatically more estrogen effect in every tissue, because the effect depends on local conversion and local receptor context. Second, estrone is most useful read next to estradiol, since the relationship between them says more than either figure alone. A clinician reviewing the panel considers both values, the direction of travel across repeat tests, and what the person is actually experiencing.
There is no single universal estrone reference range. Labs set their own based on the assay they run, plus sex, age and menstrual or menopausal status, and the range printed on your report is the one that applies to your sample.
That is not a hedge, it is how estrone testing works. Immunoassay and mass spectrometry methods produce different numbers at the low end, and a result that sits mid-range on one platform can read differently on another. Comparing an estrone value against a range copied from the internet, or against a friend's result from a different lab, is the most common interpretation error with this marker.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Estrone (E1), men | Set by the testing lab and printed on the report, varies by assay | None stated here, read against the lab's own range |
| Estrone (E1), women | Set by the testing lab and printed on the report, varies by cycle phase and menopausal status | None stated here, read against the lab's own range |
| Estradiol (E2), men | 10 to 40 pg/mL | 20 to 35 pg/mL |
| Estradiol (E2), women | 15 to 500 pg/mL | 30 to 400 pg/mL |
The estradiol figures above are typical lab reference ranges, and reference ranges vary by lab, age and sex. The FitScript optimal ranges shown are optimization targets, not diagnostic cut-offs, and a value outside them is a prompt for a conversation rather than a conclusion. Estradiol is included here only because estrone is interpreted against it, and the dedicated estradiol guide linked earlier covers that marker properly.
When you look at your own estrone result, read three things together. The number, the units, and the range the lab printed beside it. If you are tracking change over time, keep the lab and the timing consistent, because a change in method can look like a change in biology.
A higher than expected estrone value means more estrone was circulating in that sample than the lab's range predicts for someone of your sex and stage. It does not name a cause by itself.
Several things can push the number up. Greater aromatase capacity, which tracks with adipose mass, increases peripheral conversion of androgens into estrone 1. A higher supply of androgen precursor from the adrenal glands or ovaries gives aromatase more raw material. Timing matters before menopause, since cycle phase shifts estrogen substantially. Pregnancy changes estrogen production completely. Slower clearance, because the liver and gut handle estrogen metabolites, can raise what stays in circulation. Assay differences and sample handling account for some of the variation too.
The useful next step is not to chase the single number. It is to look at the pattern. Is estradiol high, low or mid-range alongside it? What are FSH and LH doing? What is SHBG, which influences how much hormone is free to act? Are androgens elevated as well, suggesting more substrate upstream? That pattern, plus symptoms and history, is what a clinician works from.
Some situations deserve attention sooner rather than later regardless of what a hormone panel says. Bleeding after menopause, a new breast lump, or any new and unexplained symptom is worth raising with a clinician promptly. A suboptimal or out-of-range hormone value is never a reason to ignore a symptom, and it is never a reason to assume the worst either.
A lower than expected estrone value means less estrone was circulating than the lab's range predicts, and like a high result, it points to a question rather than an answer.
Low readings can reflect low overall estrogen production, which is expected in some stages of life and unexpected in others. They can reflect limited substrate, since estrone depends on androgen precursors from the adrenal glands and ovaries. Very low body fat reduces peripheral conversion capacity. Ovarian insufficiency lowers the upstream contribution, which is why FSH is read alongside. Some low results are partly technical, because immunoassays lose precision at the bottom of their range and can under-read or over-read small concentrations.
Context decides what the number means. A low estrone in a premenopausal person early in the follicular phase is a different observation from the same value in someone with absent periods, and both are different from a low value after menopause. Symptoms matter here as much as the figure. Changes in cycle regularity, sleep, mood, vaginal dryness, bone health history and recovery from training all belong in the conversation.
The sequence is the same as with any marker. Note what the value shows, consider what it may reflect in your particular context, then take it to a clinician who can order the right follow-up, repeat the test if timing was the issue, and decide whether anything further is warranted. A single low number is a starting point for that discussion, not a label.
Several ordinary, non-clinical factors influence where an estrone result lands, which is why preparation and timing matter.
Age and menopausal status are the largest single influences, because they determine whether the ovaries or peripheral tissue dominate production. Cycle phase comes next for anyone still cycling, since estrogen output changes substantially across a month. Body composition shapes conversion capacity, as described above. Pregnancy raises estrogen production markedly.
Lifestyle inputs also appear in the data. Research suggests that alcohol intake is associated with higher endogenous sex hormone levels in women 4. Research suggests that neighborhood walkability is associated with differences in sex steroid hormone levels in women 5, which is one way the environment around daily movement shows up in biology. Neither finding converts into a prescription for any individual, and neither should be read as a promise that changing one habit will move a number by a predictable amount.
Two practical points. Share your full medicine and supplement list with the clinician reviewing the panel, because some products may influence hormone measurements or the assays used. And keep the conditions of testing stable across repeats, which means the same lab, a comparable time of day, and a comparable point in the cycle where that applies. Consistency is what turns a series of results into a trend you can actually read.
Estrone is measured in a standard blood draw, usually from a vein in the arm, and reported in picograms per millilitre on most panels.
Two analytical approaches are common. Immunoassay is fast and widely available but less precise at low concentrations. Liquid chromatography with tandem mass spectrometry separates steroids by mass before measuring them, and labs regard it as better suited to the low concentrations typical of postmenopausal and male samples. Some panels report estrone sulfate instead of or in addition to estrone, because the sulfate pool is larger and more stable, and it gives a smoother picture of overall estrogen supply.
Timing depends on who is being tested. For someone with regular cycles, the day of the cycle should be recorded and chosen deliberately, often early follicular for a baseline. For someone who is postmenopausal or male, cycle timing is irrelevant and consistency of lab and method matters more. Fasting is generally not required for estrone itself, though other markers drawn at the same time may call for it, so follow the instructions attached to the full panel.
One result is a snapshot of a system that moves. Interpretation improves when the value is placed next to prior results, next to the rest of the hormone panel, and next to what you are experiencing. FitScript builds that context by testing 150+ biomarkers per year, with Atlas, its AI health advisor, reading each marker against the rest of the panel before a licensed provider reviews anything further.
Estrone is most informative as part of a group, because every input and output around it is measurable.
Estradiol is the first companion, since the two interconvert and the relationship between them carries information neither figure gives alone. FSH and LH show what the pituitary is asking the ovaries to do, which separates a low estrogen reading caused by declining ovarian output from one with a different explanation. SHBG matters because it binds sex hormones in circulation and influences how much is free to act at tissue level, so two people with identical total hormone values can have different free fractions.
Androgens belong in the picture too. Total and free testosterone, DHEA-S and androstenedione describe the substrate pool that aromatase draws on, and a high estrone with high precursors reads differently from a high estrone with normal ones. Progesterone, in someone still cycling, confirms whether ovulation occurred and anchors the timing of the draw.
Beyond the sex hormones, markers of metabolic health and liver function add useful context, because body composition influences conversion and the liver influences clearance. Thyroid markers are often included in a general panel for the same reason, as hormone systems are read together rather than in isolation.
The goal of grouping markers is not more numbers. It is fewer ambiguous ones. A panel lets a clinician distinguish between an upstream signalling change, a substrate change, a conversion change and a clearance change, which a single estrone value can never do.
Estrogens act well beyond reproductive tissue, which is why estrone is of interest after the ovarian supply of estradiol declines.
Estrogen receptors appear in bone, brain, blood vessels, skin and metabolic tissue. Research suggests that estrogen acts as a regulator of bioenergetic systems in the brain and body, including pathways that govern how cells generate and use energy 6. That breadth is part of why the menopause transition is experienced as a whole-body change rather than a reproductive one.
Estrone enters this picture as a contributor to total estrogen exposure once ovarian output falls, since peripheral conversion continues to supply estrogen to tissue throughout the body 1. Its weaker receptor activity and its distinct actions mean it is not a like-for-like replacement for estradiol, and the amount produced varies widely between individuals.
What this does not support is reading symptoms backwards from a number. Fatigue, sleep disruption, mood change, bone density concerns and cognitive complaints all have multiple possible contributors, and no single estrogen value explains them. The sensible use of estrone here is as one input into a clinical assessment that also considers symptoms, history, other markers and time. Any decision about what to do next belongs to a licensed provider who evaluates the whole person, not to a lab value.
Yes, men produce estrone through the same aromatase pathway, and it is part of normal male physiology rather than an anomaly.
In men, aromatase in fat, liver, bone, brain and other tissue converts androgens into estrogens 1, so estrogen status in men is largely a function of how much androgen is available and how actively it is being converted. Estrogen is not an unwanted by-product in male biology. It contributes to bone maintenance, and it participates in the feedback loops that regulate the reproductive axis.
In practice, estradiol is measured more often than estrone in men, usually with a sensitive method because male concentrations sit low on most assays. Estrone may be added when a clinician wants a broader view of estrogen supply, for example when body composition, breast tissue changes or androgen results raise a question that estradiol alone has not answered.
The interpretation rules do not change by sex. A high or low estrone in a male panel is an observation that may reflect conversion capacity, substrate availability or clearance, and it is read with testosterone, SHBG, LH and FSH rather than on its own. No value on its own establishes a condition, and no value on its own establishes that anything needs to change.
Any result outside the lab's reference range is worth discussing, and so is a result inside the range that does not match how you feel.
Bring the conversation forward sooner if you have new or unexplained symptoms, particularly bleeding after menopause, breast changes, periods that stop or become irregular without explanation, or symptoms that are getting worse rather than settling. Those situations are worth discussing with a clinician promptly, independent of what a hormone number shows. In people with a personal or family history of hormone-sensitive conditions, results are usually interpreted with extra care and in the context of that history.
What a clinician does with the result is decide whether it needs repeating, whether the timing or method explains it, whether other markers should be added, and whether anything further is appropriate for you specifically. Decisions about any prescription-based next step are made by a licensed provider after reviewing the full picture, never from one value on a page.
This page is educational and is not medical advice. Discuss your own results, and any treatment decision that follows, with a clinician or licensed provider who knows your history.
It measures how much estrone is circulating in your blood at the moment the sample is taken, usually reported in picograms per millilitre. Some panels also report estrone sulfate, a stored form that gives a steadier picture of estrogen supply. The result is interpreted alongside estradiol, FSH and your symptoms rather than on its own.
No. Estrogen is the name for a family of hormones, and estrone is one member of it, along with estradiol and estriol. Estrone is a weaker estrogen at the receptor than estradiol, and it becomes the most abundant one after menopause.
There is no single universal figure. Each lab sets its own reference range based on the method it uses and on sex, age and menopausal or cycle status, and that range is printed next to your result. Compare your value with the range on your own report rather than with a number from another lab.
Usually, yes. The two estrogens convert back and forth, so the relationship between them tells a clinician more than either number alone. FSH, LH, SHBG and androgens are often added to show what is driving the pattern.
Men produce estrone through the same pathway, so it can be measured in men, although estradiol is tested more often. A clinician may add estrone when a broader view of estrogen supply is useful, for example alongside testosterone and SHBG. Whether it belongs on your panel is a decision for the clinician ordering the test.
Fat tissue contains aromatase, the enzyme that converts androgens into estrone, so body composition is one of the factors a clinician weighs when reading a result. More converting tissue generally means more capacity to produce estrone outside the ovaries. A higher result in that context is an observation to discuss, not a diagnosis.
If you still have cycles, the day of the draw should be chosen deliberately and recorded, because estrogen changes substantially across a month. Many clinicians use an early follicular draw for a baseline. After menopause, cycle timing no longer applies, and keeping the same lab and method matters more.
Take the full report to a clinician rather than acting on the single value. They can judge whether timing, body composition or the assay explains it, whether a repeat test is sensible, and which other markers would clarify the picture. Any next step, including anything requiring a prescription, is decided by a licensed provider who has reviewed your history.